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Key Points
The presence of a mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 is
highly specific for secondary AML.
Secondary-type mutations define an s-AML–like disease within t-AML and elderly de novo AML
that underlies clinical heterogeneity.

Abstract
Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary AML [sAML]), after leukemogenic therapy (therapy-related AML [t-AML]), or without an identifiable prodrome
or known exposure (de novo AML). The genetic basis of these distinct pathways of AML development has
not been determined. We performed targeted mutational analysis of 194 patients with rigorously defined sAML or t-AML and 105 unselected AML patients. The presence of a mutation in SRSF2, SF3B1, U2AF1,
ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was >95% specific for the diagnosis of s-AML. Analysis of
serial samples from individual patients revealed that these mutations occur early in leukemogenesis and
often persist in clonal remissions. In t-AML and elderly de novo AML populations, these alterations define
a distinct genetic subtype that shares clinicopathologic properties with clinically confirmed s-AML and
highlights a subset of patients with worse clinical outcomes, including a lower complete remission rate,
more frequent reinduction, and decreased event-free survival. This trial was registered at
www.clinicaltrials.gov as #NCT00715637.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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Introduction
Acute myeloid leukemia (AML) is a biologically heterogeneous disease that can be classified into 3
distinct categories based on clinical ontogeny: secondary AML (s-AML) represents transformation of an
antecedent diagnosis of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN),
therapy-related AML (t-AML) develops as a late complication in patients with prior exposure to
leukemogenic therapies, and de novo AML arises in the absence of an identified exposure or prodromal
stem cell disorder. It is not known whether distinct somatic genetic lesions drive these different disease
subtypes or whether ontogeny-defining mutations underlie relative differences in treatment outcomes.1-3
A central goal for the study of AML, and cancer more generally, is to elucidate organizing genetic
principles that govern initiation and progression of the disease, and to link these genetic principles to
clinical phenotype. Large-scale sequencing studies have revealed the remarkable complexity of genetic
alterations that drive the pathogenesis of myeloid malignancies, including de novo AML, MDS, and MPN,
as well as clonal diversity within individual patients.4-10 It is not clear at present whether the diverse
genetic lesions in AML can be organized into a framework that reflects and informs our understanding of
disease biology and development and could potentially be used to guide therapy and improve prognostic
accuracy.
To investigate the genetic basis of AML ontogeny, we studied a cohort of s-AML and t-AML patients
enrolled in a recent phase 3 clinical trial that represented the largest prospective evaluation of the role of
induction therapy in these patient populations. Although no significant difference in outcome was observed
between treatment arms (amonafide plus cytarabine vs daunorubicin plus cytarabine), the intrinsic therapyresistance and prognostic adversity of s-AML and t-AML was confirmed, with an overall complete
remission (CR) rate of 45% and median overall survival (OS) of 7 months.11 The rigorous eligibility
criteria, uniform treatment, and prospective data collection on this trial afforded a unique opportunity to
evaluate the distinctive genetics and clinical associations of these high-risk and understudied leukemia
subtypes.

Methods
Patient samples
A total of 433 patients with s-AML (n = 216) or t-AML (n = 217) who were enrolled in the ACCEDE trial
were considered for inclusion in this study. Patients were excluded only if they did not have available
diagnostic bone marrow tissue. Reasons for samples unavailability include presence of only a decalcified
core biopsy (unsuitable for sequencing) or reclamation of central review material by participating
institutions. The clinical characteristics and geographic origins of the patients included in this study are
similar to those of the entire trial cohort (supplemental Tables 1 and 2, available on the Blood Web site). In
total, 194 patients from 81 sites in 22 countries were included in the study cohort: 93 had s-AML, defined
by the histologic documentation of antecedent MDS or chronic myelomonocytic leukemia (CMML)
according to World Health Organization (WHO) criteria at least 3 months before study entry; 101 patients
had t-AML, 18 of whom had an interval diagnosis of therapy-related MDS (t-MDS), defined according to
the protocol as AML developing any time after documented exposure to specific leukemogenic therapies
for a nonmyeloid condition, including alkylating agents, platinum derivatives, taxanes, topoisomerase II
inhibitors, antimetabolites, external beam radiotherapy to active marrow sites, and therapeutic systemic
radioisotopes. Paired samples obtained at the time of MDS diagnosis and s-AML were available for 17
subjects, and paired samples from s-AML and CR were available for 16 subjects. All patients provided
written informed consent with the approval of the appropriate ethics committees and in accordance with
the Declaration of Helsinki. AML diagnosis was confirmed and treatment response assessed by central
pathology review. Cytogenetic analysis was performed by a central laboratory and interpreted per
International System for Human Cytogenetic Nomenclature (2013).12 The median follow-up time,
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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calculated from initiation of treatment, was 9.5 months. Remission samples used for serial analyses were
obtained at protocol-specific time points (day 37 ± 4 of induction or reinduction, earlier upon count
recovery, or later in the case of bone marrow hypocellularity) and confirmed to represent morphologic
remission (bone marrow blasts <5%) by local and central pathology review. The median time to remission
was 38 days after start of cycle 1 (range 29-74). A validation cohort consisted of 105 unselected AML
patients treated at Dana-Farber Cancer Institute (DFCI).
DNA sequencing and mutation analysis
Library construction and sequencing. Target regions of 82 genes, selected on the basis of their known or

suspected involvement in the pathogenesis of myeloid malignancies or bone marrow failure, were enriched
using the Custom SureSelect hybrid capture system (Agilent Technologies). Sequencing was focused on
specific mutational hotspots in NPM1, IDH1, IDH2, SRSF2, U2AF1, SF3B1, FLT3, KIT, CBL, CBLB,
BRAF, CSF1R, JAK2, MPL, STAT3, GNAS, and SETBP1 and the entire coding regions, including
canonical splice sites, of all other genes. A list of genes and the genomic coordinates of all target regions
are provided in the supplemental information (supplemental Tables 3 and 4). Native genomic DNA
extracted from bone marrow aspirate slides (supplemental Methods and supplemental Figure 1) was
sheared and library constructed per manufacturer protocol. Libraries were pooled at 48 samples per lane in
equimolar amounts totaling 500 ng of DNA. Each pool was hybridized to RNA baits, consisting of 8811
probes, spanning 311.266 kbp. Each capture reaction was washed, amplified, and sequenced on 2 lanes of
an Illumina HiSeq 2000 100-bp paired-end run. Germline DNA was uniformly unavailable for analysis.
Variant calling and annotation. Fastq files were aligned to hg19 version of the human genome with BWA

0.6.2. Single-nucleotide and small indel calling was performed with samtools-0.1.18 mpileup and Varscan
2.2.3. FLT3-ITD analysis performed using Pindel 0.2.4 at genomic coordinates chr13:28 608 000-28 608
600 and confirmed by Sanger sequencing (5ʹ-GCAATTTAGGTATGAAAGCCAGC-3′ and 5′CTTTCAGCATTTTGACGGCAACC-3ʹ). Variants were annotated with cDNA and amino acid changes,
number of reads supporting the variant allele, population allele frequency in 1000 Genomes release 2.2.213
and the Exome Sequencing Project,14 and presence in Catalogue of Somatic Mutations in Cancer, version
64.15 Variants were excluded if there were fewer than 15 total reads; if they fell outside of the target
coordinates, had excessive read-strand bias, or had an excessive number of variant calls in the local region;
or caused synonymous changes. All mutations (supplemental Table 5) and variants of unknown
significance (supplemental Table 6) are included in tabular form in the supplemental information. The
distribution of gene-specific variant allele fractions is displayed in supplemental Figure 3.
Analysis of the publicly available exome- and genome-level data from The Cancer Genome Atlas (TCGA)
de novo AML cohort was restricted to the same genomic coordinates as our focused analysis of the s-AML
and t-AML cohorts, and variants were identified and annotated using the same criteria. For the DFCI
cohort, DNA was extracted from fresh bone marrow aspirate or peripheral blood samples and coding
regions of 275 cancer-associated genes were enriched using the Custom SureSelect hybrid capture system
(Agilent Technologies) as previously described.16 A list of sequenced genes is provided in the
supplemental appendix (supplemental Table 7). All genes required to ascertain genetic ontogeny class were
included in the validation platform.
Statistical methods
OS was calculated from the date of treatment initiation to the date of death. Surviving patients were
censored at the date on which they were last known to be alive. OS curves were estimated using the
Kaplan-Meier method, compared using a log-rank test, and analyzed using a univariable Cox model, and
the significance of hazard ratio significance was assessed by Wald test. Associations of continuous
measures between groups were assessed using a Wilcoxon rank-sum test and categorical variables were
assessed using a Fisher exact test. P values are unadjusted, 2-sided, and considered significant at .05.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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Event-free survival was calculated from date of diagnosis to the date of death, relapse, or confirmation of
no remission.

Results
Ontogeny-defining mutations in s-AML
To investigate the somatic genetic lesions in cases of AML that develop following an antecedent MDS or
CMML, we isolated DNA from the diagnostic bone marrow aspirates of 93 rigorously defined s-AML
patients enrolled on the ACCEDE trial and sequenced 82 genes that are recurrently mutated in myeloid
malignancies or implicated in the biology of bone marrow failure. In total, we identified 353 singlenucleotide variants and small insertions or deletions affecting 40 genes (supplemental Figure 1), with at
least 1 mutation detected in 96.8% (90/93) of cases (Figure 1A). The most frequently mutated genes were
those involved in RNA splicing (55%), DNA methylation (46%), chromatin modification (42%), RAS
pathway signaling (42%), transcriptional regulation (34%), and the cohesin complex (22%).
The spectrum of genetic lesions in our s-AML cohort is notably different from previously described cases
of de novo AML.1-5 We therefore compared the genetic profile of our s-AML cases with 180 cases of
non–M3 de novo AML reported in The Cancer Genome Atlas, analyzing all genetic data through the same
computational pipeline. We identified 3 distinct and mutually exclusive patterns of mutations. First, 8
genes were mutated with >95% specificity in s-AML compared with de novo AML, including SRSF2,
SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, hereafter named “secondary-type” mutations (
Figure 1B). These 8 genes are also commonly mutated in MDS,2,4,6-9,17 suggesting that they may
primarily drive the dysplastic differentiation and ineffective hematopoiesis that is characteristic of MDS,
without efficiently promoting development of frank leukemia.
Second, we identified 3 alterations that were significantly underrepresented in s-AML compared with de
novo AML, including NPM1 mutations (P < .0001), MLL/11q23 rearrangements (P = .0002), and CBF
rearrangements (P < .0001). We termed this set of lesions de novo-type alterations. NPM1 mutations were
identified in only 5.4% (5/93) of s-AML subjects, none of whom had concurrent secondary-type or TP53
mutations.
Third, mutations in the TP53 gene have been associated with a distinct and dominant clinical phenotype in
myeloid malignancies, including a complex karyotype, intrinsic therapy resistance, and very poor
survival.18,19 In our s-AML cohort, cases with TP53 mutations (n = 14, 15.1%) had more complex
karyotypes (mean alterations per case = 10.3 vs 1.0, P < .0001) and reduced OS (median OS = 4.0 vs 8.5
months, hazard ratio [HR] = 2.00, P = .044) relative to s-AML without TP53 mutations (supplemental
Figures 3 and 4). All other mutations identified were not specific to either AML subtype and were thus
labeled “pan-AML” mutations.
We therefore propose 3 distinct genetic ontogenies for AML defined by the presence of (1) secondary-type
mutations, (2) de novo–type or pan-AML mutations, or (3) TP53 mutations.
Genetic classification of therapy-related AML
We next applied our genetic ontogeny-based classification to t-AML, a heterogeneous disease unified only
by a clinical history of exposure to leukemogenic therapy.20 We reasoned that a genetic classifier could
allocate t-AML patients into more uniform groups and inform our understanding of therapy-related
leukemogenesis.21,22 Therefore, we analyzed a cohort of 101 t-AML patients enrolled on the ACCEDE
trial using the same sequencing platform as the s-AML cohort. In total, we identified 296 single-nucleotide
variants and small insertions or deletions affecting 43 genes (supplemental Figure 1), with at least 1
mutation detected in 97% (98/101) of cases (Figure 2).
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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Among subjects with clinically defined t-AML, 33% (34/101) harbored secondary-type mutations in
SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2; 23% (23/101) of patients had TP53
mutations; 47% (47/101) had only de novo or pan-AML alterations. Of note, 3 patients had both
secondary-type and TP53 mutations and are subsequently categorized in the TP53 mutated subgroup only.
An interval diagnosis of t-MDS was more common in t-AML patients with secondary-type than de
novo/pan-AML mutations (29.4% vs 8.5%, P = .019) (supplemental Figure 6). There were no differences
in CR rate among t-AML patients based on ontogeny group (Figure 3A). However, patients with
secondary-type (36.8%, P = .022) and TP53 mutations (54.5%, P = .004) were significantly more likely to
require multiple induction cycles than patients with de novo/pan-AML mutations (7.4%) (Figure 3B),
suggesting relative chemoresistance in these groups.
We next asked whether t-AML patients as a whole possessed a shared set of clinical characteristics or
instead conformed to genetic ontogeny classes independent of prior therapy. t-AML patients with
secondary-type mutations were significantly older (62.7 vs 53.4, P = .002) and had significantly more
recurrent driver mutations (4.1 vs 2.5, P < .0001) than t-AML patients with de novo/pan-AML mutations (
Figure 3C). In fact, t-AML with secondary-type mutations closely resembled clinically defined TP53unmutated s-AML without prior exposure to leukemogenic therapy with regards to age (62.7 vs 62.3),
male predominance (male = 65% vs 69%), number of recurrent myeloid driver mutations per case (4.1 vs
4.0), and frequency of chromosome 5 or 7 abnormalities (15.4% vs 16.2%). By contrast, t-AML patients
with genetically defined de novo AML closely resembled clinically defined de novo AML, reflected by
similar frequencies of mutations in specific genes, including NPM1, FLT3, DNMT3A, TET2, IDH1/IDH2,
and WT1.2,4
Similar to TP53-mutated AML without prior therapy, TP53 mutations in t-AML were associated with a
highly complex (mean alterations 7.5 vs 1.7, P < .0001), often monosomal karyotype, with frequent
abnormalities of chromosomes 5 and 7.18 The mean number of recurrent driver mutations in TP53-mutated
t-AML cases was lower than in t-AML cases with secondary-type mutations (1.9 vs 4.1 P < .0001) (
Figure 3C), and 39% harbored no additional point mutations in known myeloid driver genes, consistent
with previous findings of TP53-mutated myeloid malignancies.19
Together, these data indicate that prior exposure to leukemogenic therapy does not define a genetically
conforming “t-AML” ontogeny. Rather, t-AML can be separated into 3 groups that vary in prevalence
across age groups (Figure 3D), each bearing more similarity to AML with the same genetic alterations and
no leukemogenic exposure than to t-AML patients as a whole. Outside of the known association between
exposure to topoisomerase-2 inhibitors and MLL rearrangements, we observed no associations between
specific leukemogenic exposures and genetic ontogeny groups (Figure 3E).
Pan-AML mutations are gained at disease progression
Having organized mutations into secondary-type, TP53-defined, and de novo/pan-AML lesions, we asked
whether genes in these different ontogeny classes would have distinct functional roles during leukemic
progression. To address this question, we sequenced 17 paired MDS and s-AML bone marrow aspirate
samples from the clinical trial cohort. At the time of s-AML transformation, we detected at least 1 new
recurrent driver mutation in 59% of cases (supplemental Table 8). Patients with TP53 mutations at the time
of MDS sampling (3/17) did not gain additional mutations at disease progression (0% vs 42%, P = .051),
providing further evidence that TP53 mutations define a distinct class of myeloid malignancies.
All new mutations (100%, 18/18) fell within the pan-AML class of genes (Figure 4A and supplemental
Figure 7). The most commonly acquired mutations involved genes encoding myeloid transcription factors
(RUNX1, CEBPA, GATA2) and signal transduction proteins (FLT3 or RAS pathway), together accounting
for 78% of new mutations (Figure 4C). Notably, among 8 patients in our cohort with CEBPA mutations,

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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only one had biallelic mutations. In this case, we demonstrate that the second CEBPA mutation was a
subclonal progression event that occurred during the transition from MDS to s-AML.
Gross persistence of mutations during remission reveals reservoirs of therapy resistance
We hypothesized that poor response to chemotherapy in s-AML may be caused by the presence of
secondary-type genetic lesions that are also present in MDS. To examine the relative sensitivity of
different mutations to chemotherapy, we examined 16 paired pre- and posttreatment bone marrow
specimens from s-AML patients who achieved a morphologic CR after induction chemotherapy.
Strikingly, 69% (11/16) of s-AML remission samples had measurable persistence of disease-driving
mutations, despite achieving a morphologic CR (Figure 4B). In nearly half of these patients, we observed
selective clearance of a subset of mutations alongside a relatively chemoresistant founder clone, suggesting
the presence of genetic subclones with differential chemosensitivity. The same pan-AML mutations that
are commonly acquired at the time of s-AML transformation, including those affecting myeloid
transcription factors and signal transduction proteins, were preferentially lost in the setting of morphologic
remission with selective elimination of a genetic subclone (67%, 10/15). By contrast, mutations in TP53,
DNMT3A, TET2, and genes involved in RNA splicing or chromatin modification were rarely acquired at
disease progression and were preferentially retained with a high mutant allele fraction.
In aggregate, our analyses of serial samples demonstrate that secondary-type mutations, along with TET2
and DNMT3A, are acquired during the MDS phase of disease, are rarely gained at leukemic progression,
and are preferentially retained in clonal remission after induction chemotherapy. By contrast, other panAML mutations are less common in MDS, are frequently gained at disease progression, and are more
likely to be lost in the context of morphologic remission (supplemental Table 8).
Genetic classification of an unselected cohort of AML patients
We next asked whether our ontogeny-based genetic classifier could resolve unrecognized clinical
heterogeneity in an unselected cohort of AML patients. We collected a sequential cohort of 105 patients
with AML who were treated at our institution over the past year and whose leukemia had been subjected to
prospective sequencing of 275 cancer-associated genes (supplemental Methods). Based on clinical history,
64% of cases were diagnosed with de novo AML, 30% with s-AML and 6% with t-AML (Figure 5).
Consistent with our previous findings, patients with secondary-type mutations were older and had more
genetically complex disease compared with patients with de novo/pan-AML or TP53 mutations (Figure 6A
). The presence of a TP53 mutation was associated with karyotype complexity (mean cytogenetic
alterations 6.7 vs 0.9, P < .0001) and reduced OS (median OS = 5.4 vs 10.9 months; HR 3.35, P = .0002)
(supplemental Figure 4).
In this cohort, 42 of 67 (63%) de novo AML patients were ≥60 years old at the time of diagnosis,
consistent with the epidemiology of AML and highlighting a group of patients with a lower rate of
remission with standard induction chemotherapy.23-26 Among these older de novo AML patients, 33.3%
(14/42) had secondary-type mutations, 21.4% (9/42) had TP53 mutations, and 45.2% (19/42) had de
novo/pan-AML mutations (supplemental Figure 9). To determine whether genetic ontogeny could identify
subsets of older de novo AML patients with distinct clinical outcomes, we evaluated the rate of CR in
evaluable patients who received standard induction regimens (n = 30, 71.4%). Among patients with
secondary-type mutations, 50% (6/12) achieved CR and 50% (3/6) of these CRs required 2 induction
cycles. The CR rate among elderly de novo AML patients with secondary-type mutations closely mirrored
the CR rate among evaluable patients with clinically confirmed s-AML who received standard induction
therapy in this independent cohort (53%, 10/20). By contrast, 92% (11/12) of older patients with de
novo/pan-AML mutations achieved CR (P = .069), and only 18% (2/11) of these remissions required
reinduction (Figure 6B). Event-free survival among older de novo AML patients with secondary-type (4.2
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable

6/20

3/6/2018

Myeloid Neoplasia: Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

months, P = .059) or TP53 mutations (6.2 months P = .039) was shorter than those de novo/pan-AML
mutations (15. 7 months) (Figure 6C).
These data suggest that genetic ontogeny highlights a subset of patients with secondary-type mutations
who, based on age, genetic characteristics, and induction outcomes, may have had an unrecognized period
of antecedent myelodysplasia before AML diagnosis. In elderly AML, genetic ontogeny, even more than
clinical ontogeny, may account for relative differences in intrinsic chemosensitivity.

Discussion
AML is currently classified into 3 clinical ontogeny groups that are, in practice, defined by the ability to
document an antecedent MDS phase (s-AML), previous leukemogenic exposures (t-AML), or the absence
of both (de novo AML). Disease classification is thus intrinsically inexact and depends on the availability
of prior clinical data rather than objective criteria at the time of diagnosis. Genomic discovery efforts have
revealed remarkable genetic heterogeneity in AML, but genetic findings have not been broadly linked to
leukemia ontogeny or clinical classification. By studying a cohort of rigorously defined s-AML cases, we
defined a core set of mutations that is highly specific to cases of AML arising after MDS. Based on the
presence of secondary-type, TP53, or de novo/pan-AML–type mutations, we defined 3 genetic ontogeny
groups that facilitate an objective classification of AML development that is agnostic to clinical history.
In our initial cohorts, as well as in an independent, unbiased collection of AML cases, genetic ontogeny
was associated with characteristic phenotypes, irrespective of clinical ontogeny assignment. AML with
secondary-type mutations tends to occur in older individuals and has approximately 4 mutations in
myeloid driver genes per case, whereas AML with de novo/pan-AML alterations is more common in
younger individuals and has fewer co-occurring driver alterations. AML with TP53 mutations has highly
distinctive characteristics, including marked karyotype complexity with multiple monosomies, a paucity of
driver comutations, and very short survival.
We applied our genetic ontogeny-based classifier to 2 heterogeneous AML cohorts: a well-defined group
of t-AML cases and a collection of sequential, unselected AML cases. In both cohorts, we resolved wellrecognized clinical heterogeneity into clearly distinct genetic subgroups. We found that one-third of
clinically defined t-AML cases display both genetic and clinical characteristics that are indistinguishable
from clinically defined s-AML. Similarly, in elderly AML patients without a known prior diagnosis of
MDS, one-third of cases have secondary-type genetics and clinically resemble s-AML, indicating that
many older patients with apparent de novo AML actually transit through an unrecognized MDS prodrome.
Our results also suggest that intrinsic chemoresistance in older AML patients may be enriched in patients
with secondary-type mutations, consistent with a long-postulated explanation for lower response rates in
these patients. By contrast, older de novo AML patients who do not harbor secondary-type or TP53
mutations, those with true biologic de novo AML, may have marked chemosensitivity, similar to younger
patients with de novo disease and thus defining a group of older patients with better than expected clinical
outcomes.
Genome-level analysis has demonstrated that clinical transformation of MDS to s-AML is associated with
subclonal disease progression, marked by genetic evolution with acquisition of numerous recurrent and
nonrecurrent somatic mutations.9 Detailed interrogation of MDS clonal architecture has further shown that
no single gene is uniformly mutated in the disease-founding clone, suggesting a need for identifying more
generalized principles of disease initiation and progression.17 By performing serial assessments before and
after disease progression, as well as before and after induction chemotherapy, we resolved s-AML into a
composite set of genetic lesions with distinct associations to ontogeny groups.
In our series of 17 MDS/s-AML pairs, we observed that newly acquired s-AML mutations were restricted
to the pan-AML ontogeny group and most commonly involved genes encoding myeloid transcription
factors or members of the RAS/tyrosine kinase signaling pathway. In contrast, secondary-type lesions and
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4342352/?report=printable
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TP53 mutations were commonly seen in MDS and were not newly gained at leukemic transformation. By
evaluating these data in the context of our genetic ontogeny classes, we provide a general framework for
functional interpretation of myeloid driver alterations, whereby mutations can be grouped into those that
tend to occur as early events (TET2, DNMT3A, TP53, and secondary-type mutations) and those that tend to
drive progression subclones (tyrosine kinase/RAS pathway, myeloid transcription factors). As such,
mutations affecting TK/RAS signaling and myeloid transcription factors may be informative for detecting
reemergence or retransformation of AML in s-AML patients who have remitted to clonal hematopoiesis.
Our findings are consistent with recent reports demonstrating the presence of somatic mutations affecting a
restricted subset of myeloid driver genes in apparently healthy individuals with normal blood counts.27,28
Our results in 16 s-AML diagnosis/remission pairs directly demonstrate the phenomenon of clonal
remission, revealing the persistence of disease-driving somatic mutations in remission bone marrow.29-31
By evaluating persistent mutations in the context of genetic ontogeny class, we show that pan-AML
progression mutations are preferentially lost at the time of morphologic remission, whereas secondary-type
mutations preferentially persist. We demonstrate a residual disease state, characterized by disappearance of
blast-associated genetic subclones and persistence of a primordial neoplastic clone occupying 10% to 60%
of the remission bone marrow cellularity. These results provide a plausible biological basis for the poor
outcomes of s-AML patients after chemotherapy and provide a powerful rationale for systematic,
sequencing-based investigation of remission clonality.
In each cohort (s-AML, t-AML, DFCI), ∼80% of patients with antecedent clinical MDS diagnoses had
either secondary-type or TP53 mutations, raising the questions of whether the remaining 20% of cases are
biologically distinct in some way. These cases may represent biological overlap between clinically defined
“MDS” and “de novo” AML, may reflect inadequate specificity of the current WHO criteria for MDS, or
may highlight variability in the diagnostic application of existing MDS pathologic criteria. Unfortunately,
we do not have information regarding the extent of dysplasia or the number of involved lineages on prior
bone marrow assessment of s-AML patients on this study. Nor do we have information regarding the
tempo of disease or severity of cytopenias during the antecedent MDS phase. A systematic evaluation of
MDS cases with secondary-type vs TP53 vs de novo/pan-AML mutations that integrates genetics with
clinicopathologic data, disease latency, and kinetics would inform interpretation of these results.
Although a large number of somatic mutations with tremendous combinatorial diversity can drive AML
pathogenesis, we have identified classes of mutations that define 3 clinicopathologically distinct
subgroups. Integration of molecular genetic principles into future classification systems can refine existing
clinical heuristics to support a more biologically precise disease classification.
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Figure 1

Spectrum and ontogeny specificity of myeloid driver mutations in s-AML. (A) A comutation plot shows
nonsynonymous mutations in individual genes, grouped into categories, as labeled on the left. Mutations are depicted by
colored bars and each column represents 1 of the 93 sequenced subjects. Colors reflect ontogeny specificity of mutated
genes, as described in (B). (B) Shown is the association between individual mutated genes and clinically defined s-AML
or de novo AML ontogeny, as depicted by odds ratio on a log10 scale. Colors indicate genes with >95% specificity for sAML (blue), >95% specificity for de novo AML (red), or <95% specificity for s-AML or de novo AML (yellow or
green). The number and frequency cases with mutations in each gene in s-AML and de novo AML cases are shown on the
right.
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Figure 2

Mutations in therapy-related AML. A comutation plot shows nonsynonymous mutations in individual genes, as labeled
on the left. Mutations are depicted by colored bars, and each column represents 1 of the 101 sequenced subjects. Colors
reflect ontogeny specificity of mutated genes, as described in Figure 1. Genetic ontogeny groups are labeled on the top.
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Figure 3
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Ontogeny-based genetic classification defines clinically distinct t-AML subgroups. (A-B) Induction outcomes in
clinically defined t-AML patients according to genetic ontogeny group. (A) Morphologic CR outcomes according to
genetic ontogeny group among clinically defined t-AML patients receiving standard induction chemotherapy. (B) Shown
is the number of induction cycles among t-AML patients achieving CR. (C) Within clinically defined t-AML, genetic
classification identifies subgroups with distinct characteristics, including number of recurrent driver mutations per case,
number of cytogenetic abnormalities per case, and age. In box plots, center lines show the median value, box limits
indicate the 25th and 75th percentiles, whiskers extend to the 10th and 90th percentiles, and outliers are represented by
dots. (D) Distribution of genetic ontogeny groups in t-AML patients according to age group. (E) History of prior
chemotherapy or radiation exposure based on genetic ontogeny class.
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Figure 4

Analysis of serial samples. Scatter plots showing variant allele fractions (VAF) at time of paired samples at (A) MDS and
s-AML and (B) diagnosis and morphologic CR. Colors show ontogeny specificity of mutated genes including secondarytype (blue); TP53 (green); and de novo/pan-AML subsets, including RAS pathway and myeloid transcription factors
(red), TET2 and DNMT3A (yellow), and other pan-AML (gray). Mutations were categorized as new if they were detected
in s-AML but present below 1% allele frequency in MDS (85%), or if their allele frequency increased from ≤10% in MDS
to >30% in the subsequent s-AML (15%). Mutations were labeled as selectively lost only if variant allele fraction was
<0.5% at remission. (C) Pie chart showing s-AML progression mutations by functional class. (D) Representative fish
plots from 2 cases with subclonal remissions showing clonal architecture at diagnosis (indicated by a red line—AML) and
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after treatment at time of morphologic CR (indicated by a red line—CR). In both cases, clonal remission is characterized
by disappearance of progression mutations and relative persistence of founder mutations despite the absence of bone
marrow myeloblasts.
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Figure 5

Mutations in an unselected cohort of AML patients. A comutation plot shows nonsynonymous mutations in individual
genes, grouped into categories, as labeled on the left. Mutations are depicted by colored bars, and each column represents
1 of the 105 sequenced subjects. Colors reflect ontogeny specificity of mutated genes, as described in Figure 1.
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Figure 6

Ontogeny-based genetic classification defines clinically distinct de novo AML subgroups. (A) Within clinically
defined de novo AML, genetic classification identifies subgroups with distinct characteristics, including number of
recurrent driver mutations per case, number of cytogenetic abnormalities per case, and age. Box plots are described in
Figure 3. (B) Proportion of patients achieving CR after intensive induction chemotherapy based on genetic subtype among
older de novo AML patients (left) and clinically defined s-AML patients (right). (C) Event-free survival in clinically
defined de novo AML patients age ≥60 years according to genetic ontogeny group. Curves show patients with de
novo/pan-AML (red), secondary-type (blue), and TP53 (green) mutations.
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